Klivira
Request demo

Optimize Infectious Disease Carelon Prior Authorizations

Klivira simplifies and accelerates the complex prior authorization process for infectious disease Carelon cases, ensuring timely access to critical therapies.

Revenue cycle leaders and prior authorization teams face significant challenges managing the high volume and intricate clinical criteria for infectious disease treatments requiring Carelon (Elevance Health) approval. Delays in prior authorization for high-cost antivirals, antifungals, and OPAT regimens directly impact patient care progression and revenue realization. Klivira addresses these bottlenecks by automating key steps in the PA workflow.

Clinical Realities in Infectious Disease Prior Authorization

Infectious Disease (ID) practices frequently manage complex patient cohorts, including those requiring long-term HIV regimens, high-cost Hepatitis C virus (HCV) antivirals, or extensive Outpatient Parenteral Antibiotic Therapy (OPAT). These treatments demand meticulous documentation, often encompassing detailed clinical notes, serial lab results (e.g., viral loads, CD4 counts), and comprehensive treatment plans, all critical for justifying medical necessity to utilization management entities like Carelon.

Common Carelon PA Triggers in Infectious Disease

  • High-cost antiviral medications (e.g., direct-acting antivirals for HCV, select HIV regimens, CMV, RSV antivirals)
  • Specific antifungal agents (e.g., echinocandins, voriconazole, posaconazole)
  • Outpatient Parenteral Antibiotic Therapy (OPAT) for prolonged IV antibiotic administration
  • Advanced diagnostic imaging for infection localization (e.g., PET/CT for osteomyelitis, complex abscesses)
  • Certain interventional procedures related to infection management (e.g., complex debridement, hardware removal in prosthetic joint infections)

EMR and Payer Touchpoints in ID Workflows

The prior authorization workflow for infectious disease treatments involves intricate interactions between EMR systems (e.g., Epic, Cerner) and payer portals, specifically Carelon. Medication orders for high-cost drugs, referral orders for specialized ID consultations, and advanced imaging requests are common EMR triggers. Submissions to Carelon typically occur via their proprietary web portal or through electronic prior authorization (ePA) channels utilizing X12 278 transactions, requiring precise data extraction from clinical documentation.

Clinical Guidelines Informing ID Prior Authorization

  • Infectious Diseases Society of America (IDSA) guidelines for various infections (e.g., endocarditis, osteomyelitis)
  • HIV Medicine Association (HIVMA) guidelines for HIV treatment and prevention
  • American Association for the Study of Liver Diseases (AASLD) guidelines for Hepatitis C management
  • National Comprehensive Cancer Network (NCCN) guidelines for immunocompromised patients with infections
  • Centers for Disease Control and Prevention (CDC) recommendations for specific infectious diseases

Klivira's Automation for Infectious Disease Carelon PAs

Klivira integrates directly with leading EMRs via SMART on FHIR and automates the extraction of relevant clinical data needed for Carelon prior authorizations in infectious disease. Our platform intelligently populates X12 278 forms and payer-specific fields for high-cost antivirals, antifungals, and OPAT, significantly reducing manual data entry and improving submission accuracy. This streamlined process ensures that the specific clinical criteria required by Carelon are met efficiently, accelerating approval times and minimizing administrative burden for ID practices.

Data Integrity and Compliance Considerations

Ensuring the integrity of Protected Health Information (PHI) and adherence to HIPAA regulations is paramount when automating prior authorizations. Klivira's platform is designed with robust security protocols to protect ePHI during data exchange between EMRs and payer systems. Organizations should consult with their compliance teams to ensure that automated workflows align with their specific policies and any evolving regulatory requirements, such as those related to CMS-0057-F.

Frequently asked questions

How does Klivira handle specific Carelon documentation requirements for OPAT prior authorizations?

Klivira's platform is configured to identify and extract the specific clinical data points that Carelon typically requires for OPAT, such as infection type, duration of therapy, IV access details, and monitoring plans. This ensures that all necessary documentation is compiled and submitted accurately, aligning with Carelon's medical necessity criteria.

Can Klivira integrate with our EMR to pull lab results for HIV prior authorizations?

Yes, Klivira leverages SMART on FHIR integrations to securely access and extract relevant lab results, such as viral loads and CD4 counts, directly from your EMR. This data is then automatically mapped to the appropriate fields for HIV prior authorization submissions to Carelon, reducing manual data retrieval and potential errors.

How does Klivira accelerate the prior authorization process for infectious disease cases with Carelon?

Klivira accelerates the process by automating data extraction from the EMR, intelligent form population for X12 278 and Carelon's portal, and proactive identification of missing information. This reduces the administrative time spent on each PA, allowing for faster submission and review cycles with Carelon.

Does Klivira support the inclusion of clinical guidelines like IDSA or AASLD in prior authorization submissions?

Klivira facilitates the inclusion of evidence-based justifications by allowing for easy attachment of supporting documentation, including references to IDSA, AASLD, or other relevant clinical guidelines. While Klivira doesn't interpret guidelines, it ensures that your clinical team's rationale, supported by these guidelines, is clearly presented to Carelon.

How does Klivira manage re-authorizations for long-term infectious disease regimens, such as chronic HIV therapy?

Klivira's system tracks authorization validity periods and can proactively flag upcoming re-authorization needs for long-term regimens. It streamlines the re-authorization process by pre-populating forms with existing patient data and prompting for updated clinical information, ensuring continuity of care without delays.

Related coverage

Other infectious-disease prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo